The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of Renal Disease on the Standardized Mortality Ratio and Life Expectancy of Patients With Systemic Lupus Erythematosus
Abstract
Objective: To study the effect of renal disease on the standardized mortality ratio (SMR) and life expectancy of patients with systemic lupus erythematosus (SLE). Methods: Patients whose diagnosis met ≥4 American College of Rheumatology criteria for SLE were longitudinally followed up from 1995 to 2011. The cumulative survival rate, SMR, and life expectancy were calculated, and the effect of renal involvement, histologic class of lupus nephritis, renal damage, and end‐stage renal disease (ESRD) on these parameters was evaluated. Results: Of the 694 SLE patients studied, 368 (53%) had renal disease, and the distribution of histologic classes (among 285 patients) was class I (1%), class II (6%), class III (19%), class IV (47%), class III/IV + class V (10%), and class V (16%). Renal damage was present in 79 patients (11%), and 24 (3%) developed ESRD. The age‐ and sex‐adjusted hazard ratios (HRs) of mortality in SLE patients with renal disease, those with renal damage, and those with ESRD, as compared to those without, were 2.23 (95% confidence interval [95% CI] 1.29–3.85), 3.59 (95% CI 2.20–5.87), and 9.20 (95% CI 4.92–17.2), respectively. Proliferative lupus nephritis (adjusted HR 2.28, 95% CI 1.22–4.24), but not the pure membranous type (adjusted HR 1.09, 95% CI 0.38–3.14), was associated with a significant increase in mortality. The age‐ and sex‐adjusted SMRs of SLE patients without renal involvement, those with lupus nephritis, those with proliferative nephritis, those with pure membranous nephritis, those with renal damage, and those with ESRD were 4.8 (95% CI 2.8–7.5), 9.0 (95% CI 6.7–11.9), 9.8 (95% CI 6.5–14.1), 6.1 (95% CI 2.0–14.1), 14.0 (95% CI 9.1–20.5), and 63.1 (95% CI 33.6–108.0), respectively. The life expectancy of SLE patients with renal disease and those with renal damage was reduced by 15.1 years and 23.7 years, respectively, compared to the general population. Conclusion: The presence of renal disease, in particular proliferative nephritis causing renal insufficiency, significantly reduces the survival and life expectancy of SLE patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Gladman, D., Ginzler, E., Goldsmith, C., Fortin, P., Liang, M., Sanchez‐Guerrero, J., Urowitz, M., Bacon, P., Bombardieri, S., Hanly, J., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390303 · Cited by 2,582
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
Demography, Measuring and Modeling Population Processes
Veron, J., Preston, S. H., Heuveline, P., & Guillot, M. (2002) · Population (French Edition) · doi:10.2307/1535065 · Cited by 1,709
Mortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
Prognostic factors in lupus nephritis
Austin, H. A., Muenz, L. R., Joyce, K. M., Antonovych, T. T., Kullick, M. E., Klippel, J. H., Decker, J. L., & Balow, J. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90338-8 · Cited by 773
Gladman, D. D., Urowitz, M. B., Goldsmith, C. H., Fortin, P., Ginzler, E., Gordon, C., Hanly, J. G., Isenberg, D. A., Kalunian, K., Nived, O., et al. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400506 · Cited by 759
SIMPLE METHOD TO CALCULATE THE CONFIDENCE INTERVAL OF A STANDARDIZED MORTALITY RATIO (SMR)
ULM, K. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115507 · Cited by 550
Feldman, C. H., Hiraki, L. T., Liu, J., Fischer, M. A., Solomon, D. H., Alarcón, G. S., Winkelmayer, W. C., & Costenbader, K. H. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37795 · Cited by 487
Epidemiology of systemic lupus erythematosus
Petri, M. (2002) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2002.0259 · Cited by 401
Factors predictive of outcome in severe lupus nephritis
Korbet, S. M., Lewis, E. J., Schwartz, M. M., Reichlin, M., Evans, J., & Rohde, R. D. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70262-9 · Cited by 374
Bastian, H. M., Roseman, J. M., Mcgwin, G., Alarcón, G. S., Friedman, A. W., Fessler, B. J., Baethge, B. A., Reveille, J. D., & Lumina Study Group (2002) · Lupus · doi:10.1191/0961203302lu158oa · Cited by 360
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Survival analysis and causes of mortality in patients with lupus nephritis
Yap, D. Y. H., Tang, C. S. O., Ma, M. K. M., Lam, M. F., & Chan, T. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs073 · Cited by 319
Fernández, M., Alarcón, G. S., Calvo‐alén, J., Andrade, R., McGwin, G., Vilá, L. M., Reveille, J. D., & LUMINA Study Group (2007) · Arthritis Care & Research · doi:10.1002/art.22672 · Cited by 272
Ward, M. M., Pyun, E., & Studenski, S. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380218 · Cited by 237
Prognostic determinants in lupus nephritis: a long-term clinicopathologic study
Donadio, J., Hart, G., Bergstralh, E., & Holley, K. (1995) · Lupus · doi:10.1177/096120339500400206 · Cited by 195
The very long-term prognosis and complications of lupus nephritis and its treatment
Bono, L. (1999) · QJM · doi:10.1093/qjmed/92.4.211 · Cited by 172
Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide
Mok, C. C., Ying, K. Y., Ng, W. L., Lee, K. W., To, C. H., Lau, C. S., Wong, R. W. S., & Au, T. C. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.045 · Cited by 163
Self-citationHersh, A. O., Trupin, L., Yazdany, J., Panopalis, P., Julian, L., Katz, P., Criswell, L. A., & Yelin, E. (2010) · Arthritis Care & Research · doi:10.1002/acr.20179 · Cited by 162
Prognostic factors in lupus nephritis
Mok, C. C. (2005) · Lupus · doi:10.1191/0961203305lu2057oa · Cited by 141
Self-citationMembranous nephropathy in systemic lupus erythematosus: a therapeutic enigma
Mok, C. C. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.14 · Cited by 95
Self-citationIncidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006.
Mok, C. C., To, C. H., Ho, L. Y., et al. (2008) · PubMed · Cited by 93
Self-citationSánchez, E., Rasmussen, A., Riba, L., Acevedo‐Vásquez, E. M., Kelly, J. A., Langefeld, C. D., Williams, A. H., Ziegler, J. T., Comeau, M. E., Marion, M. C., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34650 · Cited by 90
The Prognosis of Lupus Nephritis in African-Americans: A Retrospective Analysis
Bakir, A. A., Levy, P. S., & Dunea, G. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80177-6 · Cited by 89
Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese
Mok, C. (2010) · Lupus · doi:10.1177/0961203310388447 · Cited by 86
Self-citationWard, M. M. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.9792 · Cited by 64
Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus
Mok, C. C., & Tang, S. S. K. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.04.029 · Cited by 63
Self-citationUnderstanding lupus nephritis: diagnosis, management, and treatment options
Mok, C.-C. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s28034 · Cited by 61
Self-citationOutcomes in Biopsy-Proven Lupus Nephritis
Sisó‐Almirall, A., Ramos‐Casals, M., Bové, A., Brito‐Zerón, P., Soria, N., Nardi, N. N., Testi, A. C., Pérez-De-Lis, M., Díaz‐Lagares, C., Darnell, A., et al. (2010) · Medicine · doi:10.1097/md.0b013e3181f27e8f · Cited by 60
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Fanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Global epidemiology of systemic lupus erythematosus
Barber, M. R. W., Drenkard, C., Falasinnu, T., Hoi, A., Mak, A., Kow, N. Y., Svenungsson, E., Peterson, J., Clarke, A. E., & Ramsey-Goldman, R. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00668-1 · Cited by 709
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
Metadata
- Authors
- Mok, C. C., Kwok, R. C. L., & Yip, P. S. F.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2013-07-26
- Volume
- 65
- Issue
- 8
- Pages
- 2154-2160
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2151779481
- Cited by
- 261
- References
- 31
- FWCI
- 13.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.